Your browser doesn't support javascript.
loading
SARS-CoV-2 nsp14 Exoribonuclease Removes the Natural Antiviral 3'-Deoxy-3',4'-didehydro-cytidine Nucleotide from RNA.
Moeller, Nicholas H; Passow, Kellan T; Harki, Daniel A; Aihara, Hideki.
Afiliación
  • Moeller NH; Department of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis, MN 55455, USA.
  • Passow KT; Institute for Molecular Virology, University of Minnesota, Minneapolis, MN 55455, USA.
  • Harki DA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.
  • Aihara H; Department of Medicinal Chemistry, University of Minnesota, Minneapolis, MN 55455, USA.
Viruses ; 14(8)2022 08 16.
Article en En | MEDLINE | ID: mdl-36016411
ABSTRACT
The on-going global pandemic of COVID-19 is caused by SARS-CoV-2, which features a proofreading mechanism to facilitate the replication of its large RNA genome. The 3'-to-5' exoribonuclease (ExoN) activity of SARS-CoV-2 non-structural protein 14 (nsp14) removes nucleotides misincorporated during RNA synthesis by the low-fidelity viral RNA-dependent RNA polymerase (RdRp) and thereby compromises the efficacy of antiviral nucleoside/nucleotide analogues. Here we show biochemically that SARS-CoV-2 nsp14 can excise the natural antiviral chain-terminating nucleotide, 3'-deoxy-3',4'-didehydro-cytidine 5'-monophosphate (ddhCMP), incorporated by RdRp at the 3' end of an RNA strand. Nsp14 ExoN processes an RNA strand terminated with ddhCMP more efficiently than that with a non-physiological chain terminator 3'-deoxy-cytidine monophosphate (3'-dCMP), whereas RdRp is more susceptible to chain termination by 3'-dCTP than ddhCTP. These results suggest that nsp14 ExoN could play a role in protecting SARS-CoV-2 from ddhCTP, which is produced as part of the innate immune response against viral infections, and that the SARS-CoV-2 enzymes may have adapted to minimize the antiviral effect of ddhCTP.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Exorribonucleasas / COVID-19 Límite: Humans Idioma: En Revista: Viruses Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Exorribonucleasas / COVID-19 Límite: Humans Idioma: En Revista: Viruses Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos